Literature DB >> 7117356

Elimination of azlocillin in patients with biliary t-tube drainage.

U Gundert-Remy, E Weber.   

Abstract

The pharmacokinetic of azlocillin was followed in five elderly patients after biliary surgery. Total clearance was 138.6 +/- 17.7 ml/min when 2.0 g was given as an i.v. bolus injection. The half-life of the beta-phase averaged 110 min. The total clearance and the half-life of azlocillin were influenced by slight impairment of renal function (creatinine clearance 59.4 +/- 13.6 ml/min). In patients with normal liver function biliary excretion of the drug amounted to 5.3 +/- 2.8% of the dose (n = 3) and the kinetics of biliary excretion were linear. In contrast, in two patients with impaired liver function biliary excretion was 0.2% and 0.5% of the dose, and kinetic analysis of biliary excretion rates revealed at least one zero order step in the excretion process. Renal excretion of the drug amounted to 45.0 +/- 17.7% of the dose, which means that 50% of the total clearance of azlocillin has to be accounted for by metabolic clearance.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7117356     DOI: 10.1007/bf00542549

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  The excretion and concentration of terramycin in the abnormal human biliary tract.

Authors:  J ZASLOW; A ROSENTHAL
Journal:  Ann Surg       Date:  1954-04       Impact factor: 12.969

2.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

3.  Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males.

Authors:  D F DAVIES; N W SHOCK
Journal:  J Clin Invest       Date:  1950-05       Impact factor: 14.808

4.  In-vitro activity of azlocillin against Pseudomonas.

Authors:  B Chattopadhyay; I Hall
Journal:  Lancet       Date:  1979-02-17       Impact factor: 79.321

5.  Activity of azlocillin and mezlocillin against gram-negative organisms: comparison with other penicillins.

Authors:  R Wise; A P Gillett; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

6.  Azlocillin: in vitro studies of a new semisynthetic penicillin.

Authors:  D Stewart; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

7.  [Pharmacokinetics of azlocillin, a new semisynthetic, wide-spectrum antibiotic (author's transl)].

Authors:  K Wirth; M Schomerus; J H Hengstmann
Journal:  Infection       Date:  1976       Impact factor: 3.553

8.  Determination of the ureidopenicillins azlocillin, mezlocillin and bay K 4999 in plasma by high performance liquid chromatography.

Authors:  U Gundert-Remy; J X De Vries
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

9.  Antibiotics in biliary disease: the relative importance of antibiotic concentrations in the bile and serum.

Authors:  M R Keighley; R B Drysdale; A H Quoraishi; D W Burdon; J Alexander-Willians
Journal:  Gut       Date:  1976-07       Impact factor: 23.059

10.  Azlocillin and mezlocillin: new ureido penicillins.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

View more
  3 in total

1.  Pharmacokinetic comparison of 5 g of azlocillin every 8 h and 4 g every 6 h in healthy volunteers.

Authors:  R D Lander; R P Henderson; D R Pyszczynski
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

2.  Biliary excretion of olsalazine sodium in humans.

Authors:  M Ryde; S Gustavsson
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Jan-Mar       Impact factor: 2.441

3.  Drug Clearance in Neonates: A Combination of Population Pharmacokinetic Modelling and Machine Learning Approaches to Improve Individual Prediction.

Authors:  Bo-Hao Tang; Zheng Guan; Karel Allegaert; Yue-E Wu; Efthymios Manolis; Stephanie Leroux; Bu-Fan Yao; Hai-Yan Shi; Xiao Li; Xin Huang; Wen-Qi Wang; A-Dong Shen; Xiao-Ling Wang; Tian-You Wang; Chen Kou; Hai-Yan Xu; Yue Zhou; Yi Zheng; Guo-Xiang Hao; Bao-Ping Xu; Alison H Thomson; Edmund V Capparelli; Valerie Biran; Nicolas Simon; Bernd Meibohm; Yoke-Lin Lo; Remedios Marques; Jose-Esteban Peris; Irja Lutsar; Jumpei Saito; Jacobus Burggraaf; Evelyne Jacqz-Aigrain; John van den Anker; Wei Zhao
Journal:  Clin Pharmacokinet       Date:  2021-05-27       Impact factor: 5.577

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.